ImmunoGen Reports Recent Progress and 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Immunogen (IMGN) Tops Q4 EPS by 4c, FY Revenue Guidance Misses
February 8, 2019 6:36 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $12.27 million.
GUIDANCE:
Immunogen sees FY2019 revenue of $40-45 million, versus the consensus of $84.56... More
